Vickerman Investment Advisors Inc. Invests $393,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Vickerman Investment Advisors Inc. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 789 shares of the medical research company's stock, valued at approximately $393,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Adell Harriman & Carpenter Inc. raised its holdings in Thermo Fisher Scientific by 8.6% during the first quarter. Adell Harriman & Carpenter Inc. now owns 12,824 shares of the medical research company's stock worth $6,381,000 after purchasing an additional 1,012 shares in the last quarter. Concurrent Investment Advisors LLC raised its position in Thermo Fisher Scientific by 11.1% in the first quarter. Concurrent Investment Advisors LLC now owns 3,822 shares of the medical research company's stock worth $1,902,000 after acquiring an additional 382 shares in the last quarter. Simmons Bank raised its position in Thermo Fisher Scientific by 1.0% in the first quarter. Simmons Bank now owns 8,389 shares of the medical research company's stock worth $4,174,000 after acquiring an additional 86 shares in the last quarter. HM Payson & Co. raised its position in Thermo Fisher Scientific by 5.3% in the first quarter. HM Payson & Co. now owns 175,706 shares of the medical research company's stock worth $87,431,000 after acquiring an additional 8,904 shares in the last quarter. Finally, VELA Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $1,174,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $10.57 during midday trading on Monday, hitting $418.76. The company's stock had a trading volume of 2,497,096 shares, compared to its average volume of 1,976,560. The stock has a market capitalization of $158.08 billion, a price-to-earnings ratio of 24.56, a PEG ratio of 2.28 and a beta of 0.77. The stock's 50 day simple moving average is $409.18 and its 200 day simple moving average is $479.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the company posted $5.11 earnings per share. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on TMO shares. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Scotiabank cut their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Barclays cut their price objective on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, UBS Group dropped their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $604.05.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.